ALESSANDRA TOLOMELLI, WALTER CABRI
Projects for Green Innovation Lab, Center for Chemical Catalysis,
Department of Chemistry, University of Bologna, Italy

Abstract

Catalysis plays a central role in the synthesis of active pharmaceutical ingredients (APIs), offering enhanced efficiency, selectivity, and sustainability in modern pharmaceutical manufacturing. The demand for greener and more cost-effective synthesis routes has positioned catalytic methods—particularly asymmetric, enzymatic, and transition-metal catalysis—at the forefront of pharmaceutical innovation. This article explores the various types of catalysis used in API production, discusses process design considerations, and highlights future perspectives for catalysis in the pharmaceutical sector.

Introduction

The production of active pharmaceutical ingredients (APIs) involves complex chemical transformations requiring precise control over reaction conditions and product purity. Traditionally, stoichiometric methods dominated API synthesis, often leading to substantial waste and inefficiencies. Catalysis has emerged as a transformative technology in this domain, enabling reactions with higher atom economy, selectivity, and scalability (1-3).

Catalytic reactions demand rigorous design, perfect control of the chemical space and a critical evaluation of all key parameters through the integration of clear performance metrics (4) and comprehensive economic analysis.
Factors such as turnover number, selectivity, yield, cost of goods, process safety, downstream purification requirements, catalyst recyclability, and environmental impact must be thoroughly assessed early in development. Without this structured framework, even catalysts with excellent laboratory performance may prove impractical or noncompetitive for industrial-scale API synthesis.

Catalysis comprehends a wide array of tech ...